Holen Sie sich die Stockscreener-App
8.53
1.91%
0.16
Vorhandelsmarkt:
8.53
Schlusskurs vom Vortag:
$8.37
Offen:
$8.27
24-Stunden-Volumen:
44,753
Relative Volume:
1.26
Marktkapitalisierung:
$44.76M
Einnahmen:
$31.80M
Nettoeinkommen (Verlust:
$-58.49M
KGV:
-1.2373
EPS:
-6.894
Netto-Cashflow:
$-17.58M
1W Leistung:
+12.24%
1M Leistung:
+12.08%
6M Leistung:
-19.75%
1J Leistung:
-19.83%
1-Tages-Spanne:
$8.27
$8.63
1-Wochen-Bereich:
$7.16
$8.6445
52-Wochen-Spanne:
$6.4652
$16.52
Xilio Therapeutics Inc Stock (XLO) Company Profile
Firmenname
Xilio Therapeutics Inc
Sektor
Branche
Telefon
617-833-1027
Adresse
828 WINTER STREET, WALTHAM
Compare XLO vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XLO
Xilio Therapeutics Inc
|
8.53 | 44.76M | 31.80M | -58.49M | -17.58M | -6.894 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Xilio Therapeutics Inc Stock (XLO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-06 | Eingeleitet | Leerink Partners | Outperform |
| 2022-12-21 | Eingeleitet | Chardan Capital Markets | Buy |
| 2022-01-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-11-16 | Eingeleitet | Cowen | Outperform |
| 2021-11-16 | Eingeleitet | Guggenheim | Buy |
| 2021-11-16 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-11-16 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Xilio Therapeutics Inc Aktie (XLO) Neueste Nachrichten
Market Catalysts: How much upside does Xilio Therapeutics Inc have2026 Earnings & Fast Moving Stock Trade Plans - baoquankhu1.vn
Xilio plans mid-2026 IND filing for cancer therapy XTX501 By Investing.com - Investing.com Australia
Xilio Therapeutics Extends Cash Runway Through 2027 and Advances Masked Immuno-Oncology Pipeline, Including XTX501 and Multi-Specific T Cell Engagers 123 - Minichart
Xilio Therapeutics: Advancing Masked Immuno-Oncology Therapies for Improved Cancer Outcomes - Minichart
Xilio Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Xilio plans mid-2026 IND filing for cancer therapy XTX501 - Investing.com
Xilio Therapeutics 2025 10-K: Revenue $43.8M, EPS (loss) $0.00 - TradingView
Xilio Therapeutics (XLO) outlines masked immuno-oncology pipeline and big pharma deals - Stock Titan
XLO: Collaboration revenue surged and cash runway extended as pipeline advanced toward key milestones - TradingView
Xilio (NASDAQ: XLO) boosts 2025 revenue and cash runway into 2027 - Stock Titan
BRIEF-Xilio Therapeutics Q4 Net Income USD 10.36 Million - TradingView
Cancer drug developer targets 2026 trial start with cash into 2027 - Stock Titan
Xilio Therapeutics Inc Share Price USD0.0001 - Hargreaves Lansdown
If You Invested $1,000 in Xilio Therapeutics, Inc. (XLO) - Stock Titan
Volume Summary: Can Xilio Therapeutics Inc deliver alphaWeekly Stock Summary & Daily Entry Point Alerts - baoquankhu1.vn
Trading Recap: What is the long term forecast for Xilio Therapeutics Inc stockGold Moves & Community Consensus Picks - baoquankhu1.vn
Can Xilio Therapeutics Inc sustain earnings growthWeekly Gains Report & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Exit Recap: Will Boyd Gaming Corporation stock benefit from M A2026 EndofMonth & Weekly Return Optimization Plans - baoquankhu1.vn
Big Picture: Why is Xilio Therapeutics Inc stock going downWeekly Risk Report & Proven Capital Preservation Methods - baoquankhu1.vn
Analysis Recap: Whats the outlook for JB Hunt Transport Services Incs sector2026 Selloffs & Expert Curated Trade Setup Alerts - baoquankhu1.vn
Xilio Therapeutics to present data on masked cancer therapy at AACR - Investing.com Australia
Xilio Therapeutics to present data on masked cancer therapy at AACR By Investing.com - Investing.com South Africa
Xilio Therapeutics to Present Poster on XTX601 at AACR Annual Meeting 2026 - Quiver Quantitative
Xilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program ... - Bluefield Daily Telegraph
Xilio Therapeutics to Present New Preclinical Data for its - GlobeNewswire
Xilio Therapeutics (NASDAQ:XLO) Shares Down 4.8%What's Next? - MarketBeat
Xilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program Targeting CLDN18.2 at the American Association for Cancer Research (AACR) Annual Meeting - Sahm
Inflation Data: Whats the fair value of Xilio Therapeutics Inc stock2026 Pullback Review & Capital Efficiency Focused Ideas - baoquankhu1.vn
Xilio Therapeutics (NASDAQ:XLO) Sees Unusually-High Trading VolumeHere's What Happened - MarketBeat
Trading Halt: Halted at 7:50:00 p.m. ETTrading Halt: Halt News PendingXilio Therapeutics (NASDAQ:XLO) - Benzinga
Xilio Therapeutics implements 1-for-14 reverse stock split By Investing.com - Investing.com Canada
Xilio Therapeutics Announces 1-for-14 Reverse Stock Split - The Globe and Mail
Published on: 2026-03-13 07:54:21 - baoquankhu1.vn
Xilio Therapeutics implements 1-for-14 reverse stock split - Investing.com South Africa
Xilio Therapeutics (Nasdaq: XLO) enacts 1-for-14 reverse stock split - Stock Titan
XLO Forecast, Price Target & Analyst Ratings | XILIO THERAPEUTICS INC (NASDAQ:XLO) - ChartMill
Xilio Therapeutics Advances Masked Immuno-Oncology Therapies with Robust Pipeline, Strategic Partnerships, and Strong Financials (2026 Update) - Minichart
Xilio Therapeutics Updates Investor Presentation on I-O Strategy - TipRanks
Xilio Therapeutics posts investor presentation highlighting pipeline, $137.5M cash and upcoming INDs - TradingView
Cash runway to 2027: Xilio Therapeutics (NASDAQ: XLO) details I-O pipeline - Stock Titan
XLO SEC FilingsXilio Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Can Xilio Therapeutics Inc expand into new marketsJuly 2025 Gainers & Reliable Entry Point Trade Alerts - baoquankhu1.vn
Institution Moves: How sustainable is Xilio Therapeutics Inc. stock dividend payout2025 Market WrapUp & Free Expert Verified Stock Movement Alerts - Naître et grandir
Chipmakers Recap: Is Xilio Therapeutics Inc benefiting from innovation trendsJuly 2025 Trends & Smart Money Movement Tracker - baoquankhu1.vn
Xilio Therapeutics Inc expected to post a loss of 12 cents a shareEarnings Preview - TradingView
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
XLO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Press Release: Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bitget
Xilio Therapeutics to Present at the Leerink Partners Global Healthcare Conference - The Manila Times
Xilio Therapeutics announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Finanzdaten der Xilio Therapeutics Inc-Aktie (XLO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):